FDA approves Inovio's Voceryq for recurrent respiratory papillomatosis
The U.S. Food and Drug Administration has approved Inovio Pharmaceuticals' treatment Voceryq for recurrent respiratory papillomatosis, a rare throat disease. The approval sent Inovio's shares surging.
